Cerium(4+) | 16065-90-0

• 分子结构分类: 无机化合物 - 均相金属化合物 - 均相镧系化合物
• 英文名称: Cerium(4+)
• CAS: 16065-90-0
• 化学式: Ce+4
• 分子量: 140.116
• InChiKey: ITZXULOAYIAYNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.0
• 重原子数：
  1
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2-cyclohexyl-4,7-dimethoxy-1,3-benzothiazole 、 Cerium(4+) 、 硝酸铵 以 acetonitrile-water 为溶剂， 反应 1.5h， 以0.78 g (yield=88%) of 2-cyclohexyl-1,3-benzothiazole-4,7-dione is obtained的产率得到2-cyclohexyl-1,3-benzothiazole-4,7-dione
  参考文献：
  名称：

  BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS

  摘要：

  本发明涉及使用通式(I)的化合物作为cdc25磷酸酶抑制剂，特别是cdc25-C磷酸酶和CD45磷酸酶的抑制剂。其中，W代表O或S。根据本发明，通式(I)的化合物可以特别用于制备用于癌症治疗的药物。

  公开号：

  US20070293487A1

文献信息

• Method for making a volatile cerium diketonate compound
  申请人：Corning Glass Works

  公开号：US04511515A1

  公开（公告）日：1985-04-16

  A method for the synthesis of tetrakis-(6,6,7,7,8,8,8,-heptafluoro-2,2-dimethyl-3,5-octanedione) cerium (IV), [Ce(fod).sub.4 ] wherein the product is directly formed by reacting the deprotonated beta-diketonate ligand with a cerium (IV) salt, is disclosed.

  本发明揭示了一种合成四(6,6,7,7,8,8,8,-七氟-2,2-二甲基-3,5-庚二酮基)铈(IV), [Ce(fod).sub.4]的方法，其中产物是通过将去质子的β-二酮配体与铈(IV)盐直接反应形成的。
• Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors
  申请人：Galcera Contour Marie-Odile

  公开号：US20060040996A1

  公开（公告）日：2006-02-23

  The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment.

  本发明涉及使用通式(I)化合物作为cdc25磷酸酶抑制剂，特别是cdc25-C磷酸酶和CD45磷酸酶的抑制剂。其中，W代表O或S。根据本发明，通式(I)化合物特别适用于制备用于癌症治疗的药物。
• Method of making mixed metal oxide containing sulfur
  申请人：Vartuli Clarke James

  公开号：US20060270883A1

  公开（公告）日：2006-11-30

  The invention relates to a method of making Group 3 and Group 4 mixed metal oxide catalyst suitable for the decomposition of ethers to alkenes and alkanols. In an embodiment, it relates to a method of making a cerium-zirconium mixed metal oxide catalyst. In an embodiment, the catalyst made by the process of the invention is used for the production of isopropanol (IPA) from isopropyl ether (IPE).

  本发明涉及一种制备三族和四族混合金属氧化物催化剂的方法，适用于将醚分解为烯烃和醇。在一种实施例中，本发明涉及一种制备铈锆混合金属氧化物催化剂的方法。在一种实施例中，使用本发明的方法制备的催化剂用于从异丙醚（IPE）生产异丙醇（IPA）。
• Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent
  申请人：Prevost Gregoire

  公开号：US20060281736A1

  公开（公告）日：2006-12-14

  A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. According to the invention, the other anti-cancer agent is preferably chosen from: analogues of DNA bases such as 5-fluorouracil; Type I and/or II topoisomerase inhibitors such as for example camptothecin and its analogues, doxorubicin or amsacrine; compounds interacting with the cell spindle such as for example paclitaxel (Taxol); compounds acting on the cytoskeleton such as vinblastine; inhibitors of the transduction of the signal passing through the heterotrimeric G proteins; prenyltransferase inhibitors, and in particular farnesyltransferase inhibitors; cyclin-dependent kinase (CDKs) inhibitors; alkylating agents such as cisplatin; antagonists of folic acid such as methotrexate; and inhibitors of the synthesis of DNA and cell division cell such as mitomycin C. A further subject of the invention is (1R)-1-[((2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8B)-yl]-2-oxoethylamine, or a pharmaceutically acceptable salt thereof, useful as an anticancer agent.

  本发明的主题是一种产品，其中包含至少一种Cdc25磷酸酶抑制剂与至少一种其他抗癌药物相结合，用于治疗癌症的同时、分离或分散在时间上。根据本发明，其他抗癌药物优选从以下药物中选择：DNA碱基类似物，如5-氟尿嘧啶；I型和/或II型拓扑异构酶抑制剂，例如阿霉素及其类似物，多柔比星或阿姆替琴；与细胞纺锤相互作用的化合物，例如紫杉醇（紫杉醇）；作用于细胞骨架的化合物，如长春新碱；异三聚体G蛋白信号传导的抑制剂；长链烯丙基转移酶抑制剂，特别是法尼酰转移酶抑制剂；细胞周期依赖性蛋白激酶（CDK）抑制剂；碱基化剂，如顺铂；叶酸拮抗剂，如甲氨蝶呤；以及DNA合成和细胞分裂细胞的抑制剂，如丝裂霉素C。本发明的另一个主题是(1R)-1-[((2R)-2-amino-3-[(8S)-8-(环己基甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8H)-基]-3-氧代丙基}二硫基)甲基]-2-[(8S)-8-(环己基甲基)-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7(8B)-基]-2-氧代乙基胺或其药学上可接受的盐，用作抗癌剂。
• Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent
  申请人：Provost Gregoire

  公开号：US20090253685A1

  公开（公告）日：2009-10-08

  A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. According to the invention, the other anti-cancer agent is preferably chosen from: analogues of DNA bases such as 5-fluorouracil; Type I and/or II topoisomerase inhibitors such as for example camptothecin and its analogues, doxorubicin or armsacrine; compounds interacting with the cell spindle such as for example paclitaxel (Taxol); compounds acting on the cytoskeleton such as vinblastine; inhibitors of the transduction of the signal passing through the heterotrimeric G proteins; prenyltransferase inhibitors, and in particular farnesyltransferase inhibitors; cyclin-dependent kinase (CDKs) inhibitors; alkylating agents such as cisplatin; antagonists of folic acid such as methotrexate; and inhibitors of the synthesis of DNA and cell division cell such as mitomycin C. A further subject of the invention is (1R)-1-[((2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine, or a pharmaceutically acceptable salt thereof, useful as an anticancer agent.

  本发明的一个主题是一种产品，其包含至少一种Cdc25磷酸酶抑制剂和至少一种其他抗癌药物的组合，用于治疗癌症的同时、分离或时间延长的治疗。根据本发明，其他抗癌药物优选从以下选择：DNA碱基类似物，例如5-氟尿嘧啶；I型和/或II型拓扑异构酶抑制剂，例如伯氨喹、多柔比星或阿姆沙曲；与细胞纺锤相互作用的化合物，例如紫杉醇（紫杉醇）；作用于细胞骨架的化合物，例如长春新碱；通过异源三聚体G蛋白传递信号的抑制剂；戊二烯基转移酶抑制剂，特别是戊二烯基转移酶抑制剂；细胞周期蛋白依赖性激酶（CDKs）抑制剂；碱基化剂，例如顺铂；叶酸拮抗剂，例如甲氨蝶呤；以及DNA合成和细胞分裂细胞的抑制剂，例如丝裂霉素C。本发明的另一个主题是（1R）-1-[（（2R）-2-氨基-3-[(8S)-8-（环己基甲基）-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7（8H）-基]-3-氧代丙基}硫代）甲基]-2-[(8S)-8-（环己基甲基）-2-苯基-5,6-二氢咪唑[1,2-a]吡嗪-7（8H）-基]-2-氧代乙胺或其药学上可接受的盐，用作抗癌剂。